This article was originally published on Docwire News
Sarah Holstein, MD, PhD, associate professor of medicine in the Division of Oncology & Hematology at the University of Nebraska Medical Center, discusses the multiple myeloma (MM) treatment pipeline and how the introduction of these agents may change the treatment landscape.
In part two of this interview with Dr. Holstein, available November 10, she discusses targets of interest for the treatment of MM.